Abbott latest victim of FDA’s missed PDUFA dates
Executive Summary
Abbott Laboratories joins the ranks of pharma companies whose PDUFA action dates for NDAs have passed, as FDA told the company this week it needs more time to review its cholesterol drug TriLipix (ABT-335), a next-generation fenofibrate. The agency did not request additional data or extend the drug's PDUFA date. Abbott joins a long list of drug companies affected by the resource-strapped agency (1"The Pink Sheet," Sept. 29, 2008, p. 21). Abbott still expects a fourth quarter approval. It was a rough week for Abbott, as the company also received a complete response letter Oct. 20 from FDA for its NDA for a controlled-release form of hydrocodone with acetaminophen
You may also be interested in...
FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
EU To Expand Fragrance Allergen Labeling With Implications For California’s ‘Right To Know’
Companies will have more fragrance allergens to report to California health authorities if the European Union requires more than 50 additional fragrance allergens to be labeled on cosmetic products, as proposed by the Commission in September.